Pluri Inc. Share-based Payment Arrangement, Expense, after Tax
Pluri Inc. (PLUR) reported Share-based Payment Arrangement, Expense, after Tax of $3.29 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2026-09-10
- Pluri Inc. share-based payment arrangement, expense, after tax for the quarter ending 2026-06-30 was $568.00K, a 32.22% decline year-over-year.
- Pluri Inc. share-based payment arrangement, expense, after tax for the quarter ending 2026-03-31 was $1.28M, a 161.71% increase year-over-year.
- Pluri Inc. share-based payment arrangement, expense, after tax for the quarter ending 2025-12-31 was $857.00K, a 234.77% increase year-over-year.
- Pluri Inc. share-based payment arrangement, expense, after tax for the quarter ending 2025-09-30 was $637.00K, a 14.16% increase year-over-year.
- Pluri Inc. share-based payment arrangement, expense, after tax for fiscal 2026 was $3.29M, a 53.52% increase from fiscal 2025.
- Pluri Inc. share-based payment arrangement, expense, after tax for fiscal 2025 was $2.14M, a 18.14% decline from fiscal 2024.
- Pluri Inc. share-based payment arrangement, expense, after tax for fiscal 2024 was $2.62M.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $1.85M derived: sum of 2 quarters · filed 2026-09-10 | $2.71M derived: sum of 3 quarters · filed 2026-09-10 | $3.29M 10-K · filed 2026-09-10 |
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-14 | $2.14M derived: sum of 2 quarters · filed 2026-05-14 | $2.72M 10-Q · filed 2026-05-14 | $3.62M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-12-31 | $857.00K 10-Q · filed 2026-02-12 | $1.49M 10-Q · filed 2026-02-12 | $2.33M derived: sum of 3 quarters · filed 2026-09-10 | $2.82M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-09-30 | $637.00K 10-Q · filed 2025-11-12 | $1.48M derived: sum of 2 quarters · filed 2026-09-10 | $1.97M derived: sum of 3 quarters · filed 2026-09-10 | $2.22M derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-06-30 | $838.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-10 | $1.33M derived: sum of 2 quarters · filed 2026-09-10 | $1.58M derived: sum of 3 quarters · filed 2026-09-10 | $2.14M 10-K · filed 2026-09-10 |
| 2025-03-31 | $491.00K 10-Q · filed 2026-05-14 | $747.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.30M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $256.00K 10-Q · filed 2026-02-12 | $814.00K 10-Q · filed 2026-02-12 | ||
| 2024-09-30 | $558.00K 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $2.62M 10-K · filed 2025-09-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |